Obinil 120mg Capsule contains Orlistat, a potent lipase inhibitor indicated for the management of obesity. Orlistat acts locally in the gastrointestinal tract by selectively inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By blocking these enzymes, Orlistat reduces the absorption of dietary fats by approximately 30%, promoting weight loss and aiding in weight maintenance when used in conjunction with a reduced-calorie diet and exercise. Obinil 120mg is primarily prescribed for overweight and obese patients with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² in the presence of other risk factors such as hypertension, diabetes mellitus, or dyslipidemia. Clinical studies have demonstrated that Orlistat improves weight reduction and contributes to the improvement of obesity-related comorbidities, including type 2 diabetes and cardiovascular risk factors. The medication is generally well tolerated, with the most common adverse effects being gastrointestinal in nature, such as oily spotting, flatulence with discharge, and fecal urgency, which are typically related to dietary fat intake. Obinil 120mg should be used under medical supervision, and patients are advised to adhere to a nutritionally balanced, reduced-fat diet to minimize side effects and optimize therapeutic outcomes.